Margalef et al. have shown recently that inhibition of the endosomal V‐ATPase is a potential therapeutic strategy for the treatment of colorectal cancers with mutant BRAF, which is predictive of poor prognosis and therapeutic resistance [Margalef et al., 2015]. This evidence concerns the gene BRAF and colorectal cancer.